Across TCGA pan-cancer cohorts, CYCSP17 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated CYCSP17 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CYCSP17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CYCSP17 expression acts as an unfavorable survival marker.
LIHC, BLCA, and PAAD are the cancer types where CYCSP17 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.